Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$64.20T
24h Vol:
$8.52B
Dominance:
MSFT:4.79%
Stocklytics Platform
Instrument logo  CDIO
Cardio Diagnostics Holdings
CDIO
48 / 100
Penny Stock
$0.90arrow_drop_up24.31%$0.17

Performance History

Stocklytics logo
Key Stats
Open$0.74
Prev. Close$0.72
EPS-0.66
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap15856503.00
PE Ratio-
LOWHIGH
Day Range0.73
1.12
52 Week Range0.17
3.56
Ratios
P/B Ratio8.10
Revenue-
Operating M. %-29,039.51%
Earnings$0.00
Earnings Growth %-79.72%
EBITDA Margin %-
ROE %-230.77%
EPS-0.66

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

48vs 56. Market Avg.

All Score 48 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

CDIOMARKET
Value5038
Quality2540
Ownership1017
Growth5746
Dividends-37
check_circle

Cardio Diagnostics Holdings's Price discount from 1 year high of 75.94% is great compared to market average of 16.77%. This indicates CDIO could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$760.00
24H (%)arrow_drop_down1.49%
24H ($)-$11.54
MARKET CAP$739.19B
PRICE$512.81
24H (%)arrow_drop_up1.13%
24H ($)$5.78
MARKET CAP$453.09B
PRICE$149.91
24H (%)arrow_drop_up0.04%
24H ($)$0.06
MARKET CAP$357.92B
PRICE$130.06
24H (%)arrow_drop_down0.13%
24H ($)-$0.17
MARKET CAP$322.98B

About Cardio Diagnostics Holdings (CDIO)

Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Meeshanthini V. Dogan Ph.D.
Headquarters
Chicago
Employees
7
Exchange
NASDAQ
add Cardio Diagnostics Holdings to watchlist

Keep an eye on Cardio Diagnostics Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Cardio Diagnostics Holdings (CDIO)?

For Cardio Diagnostics Holdings (CDIO), the 52-week high is $3.56, which is 293.37% from the current price. The 52-week low is $0.17, the current price is 429.24% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
What is Cardio Diagnostics Holdings's (CDIO) price per share?

The current price per share for Cardio Diagnostics Holdings (CDIO) is $0.9. The stock has seen a price change of $0.18 recently, indicating a 24.31% change. This reflects the stock's recent market performance and investor sentiment.

help
Is Cardio Diagnostics Holdings (CDIO) a growth stock?

Cardio Diagnostics Holdings (CDIO) has shown an average price growth of 0.41% over the past three years. It has received a score of -2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cardio Diagnostics Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Cardio Diagnostics Holdings (CDIO) stock price performance year to date (YTD)?

As of the latest data, Cardio Diagnostics Holdings (CDIO) has a year-to-date price change of -70.42%. Over the past month, the stock has experienced a price change of -16.2%. Over the last three months, the change has been -53.11%. Over the past six months, the figure is -19.2%.

help
Is Cardio Diagnostics Holdings (CDIO) a profitable company?

Cardio Diagnostics Holdings (CDIO) has a net income of -$8.38M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -29.04K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$7.24M. Furthermore, the EBITDA is -$7.13M.

help
What is the market capitalization of Cardio Diagnostics Holdings (CDIO)?

Cardio Diagnostics Holdings (CDIO) has a market capitalization of $15.86M. The average daily trading volume is 1.24M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.